| 28.31 -2.94 (-9.41%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 42.9  |
1-year : | 49.06 |
| Resists | First : | 36.73 |
Second : | 42 |
| Pivot price | 34.06 |
|||
| Supports | First : | 28.2 |
Second : | 23.46 |
| MAs | MA(5) : | 31.33 |
MA(20) : | 34.88 |
| MA(100) : | 33.41 |
MA(250) : | 26.85 |
|
| MACD | MACD : | -1.7 |
Signal : | -1 |
| %K %D | K(14,3) : | 6.5 |
D(3) : | 12.7 |
| RSI | RSI(14): 30 |
|||
| 52-week | High : | 43.65 | Low : | 15.93 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NGNE ] has closed below the lower bollinger band by 0.9%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 52.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 31.36 - 31.51 | 31.51 - 31.64 |
| Low: | 27.86 - 28.02 | 28.02 - 28.14 |
| Close: | 28.09 - 28.33 | 28.33 - 28.52 |
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Sat, 19 Sep 2026
Several Neurogene Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Tue, 08 Sep 2026
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Fri, 14 Aug 2026
Balyasny Asset Management (NGNE) discloses 5.18% Neurogene stake via Atlas fund - Stock Titan
Thu, 23 Jul 2026
Neurogene Inc. Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Challenges - One-Time Loss Impact - careplusvn.com
Fri, 17 Jul 2026
Neurogene Inc. (NGNE) Q1 2026 Earnings: EPS Miss and No Revenue Highlight Pre-Commercial Challenges - EPS Revision Trend - careplusvn.com
Wed, 01 Jul 2026
Neurogene Inc. Stock 12‑Month Price Target Raised to $79.62, Implies 153% Upside - tradingview.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 6.9 (%) |
| Held by Institutions | 88.8 (%) |
| Shares Short | 3,040 (K) |
| Shares Short P.Month | 2,930 (K) |
| EPS | -5.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28 % |
| Return on Equity (ttm) | -45.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.42 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -5.62 |
| PEG Ratio | 0 |
| Price to Book value | 2.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|